Objectives: To evaluate the impact of a novel biopsy instrument that extends the length of the side-notch on the detection of prostate cancer in transrectal needle biopsy. Methods: We collaborated with a biopsy needle manufacturer and developed a novel biopsy instrument (PRIMECUT II long-notch type) with a 25-mm side-notch length and 28-mm stroke length to take longer tissue cores. The sampled core length, cancer detection rate, pain and complications of 489 patients who underwent transrectal biopsy using the long-notch needle were compared with those of 469 patients who underwent biopsy using a normal instrument with a 19-mm side-notch length and 22-mm stroke length. Results: The mean length of tissue taken by the long-notch needle was significantly longer than that of tissue taken by the normal-notch needle (16.3 vs 22.4 mm, P < 0.001). The overall cancer detection rate was 42.0% for the normal-notch needle and 51.1% for the long-notch needle (P = 0.005). In patients with a prostate volume of 20-40 mL, the cancer detection rate for the long-notch needle was especially higher than that for the normalnotch needle (74.2% vs 47.5%, P < 0.001). Multivariate analysis showed that the long-notch needle improved cancer detection significantly (odds ratio 1.702, P < 0.001). There were no differences of pain during biopsy and complication between the two groups. Conclusions: The novel biopsy instrument with a 25-mm side-notch can take longer tissue samples safely and has a significantly higher rate of prostate cancer detection in transrectal biopsy.
Introduction
Ultrasound-guided needle biopsy is the method used most widely for detecting prostate cancer, 1 and among the various strategies that have been developed to increase its detection rate and enhance its diagnostic value are increasing the number of cores, 2, 3 template-guided biopsy and MRI-ultrasound fusion-guided biopsy. 4, 5 Several studies have suggested that the core length actually taken influences the prostate cancer detection rate 6 and determines core quality not only in transrectal biopsy, 7 but also in transperineal biopsy. 8 We previously reported that extending biopsy cutting length increased the cancer detection rate in TRNB simulations based on 3-D prostate cancer models reconstructed from actual specimens. 9 These studies suggest that extending biopsy cutting length and taking longer sample cores could increase cancer detection rates and the diagnostic value of the cores.
Side-notch needles are widely used, and the longest notch available in needles currently on the market is 19-mm long. The Bard Magnum (Bard, Covington, GA, USA), the most widely used biopsy instrument, uses a needle with a side-notch length of 19 mm and a stroke length of 22 mm. Several studies evaluating the ability of an end-cutting biopsy instrument, the BioPince (Amedic, Kista, Sweden), to take longer sample cores when it was used with 23-mm and 33-mm stroke lengths compared the resultant cores with cores obtained using standard side-notch needles concluded that the end-cutting needle took longer cores, but had a higher failure rate.
Methods Patients and biopsy instrument
Before the present study, we collaborated with biopsy needle manufacturer, TSK Laboratory, and developed a novel biopsy instrument based on an existing instrument (PRIMECUT II; TSK Laboratory, Tochigi, Japan) with a thickness of 18-G by extending the side-notch length from 19 to 25 mm and the stroke length from 22 to 28 mm to take a longer tissue core and to reach the anterior portion of the prostate (Fig. 1) .
A total of 489 patients underwent 12-core TRNB using the novel biopsy instrument at Aichi Medical University Hospital, Nagakute, Aichi, Japan, from March 2015 to August 2017. Their sampled core length, cancer detection rate, pain and complications were compared with those of 469 patients who underwent 12-core TRNB using a conventional needle, the Bard Magnum (Bard, Covington, GA, USA) with a sidenotch length of 19 mm and stroke length of 22 mm, at our institution from April 2009 to June 2015. For both groups, each patient's age and PSA value at the biopsy were obtained from hospital medical records.
Ethical approval of this study was granted by the ethics committee of the Aichi Medical University (No. 2015-H110).
Biopsy method and pathological diagnosis
All patients received 10 mL of 2% lidocaine gel intrarectally, and before biopsy the volume of the prostate was calculated using the ellipsoid formula. A total of 12 cores, including lateral and medial cores from both sides of the apical, medial, and basal thirds of the prostate, were obtained under TRUS from every patient. A tip of needle was placed just behind the posterior prostatic capsule. All biopsies were carried out in a standardized way. The long-notch needle tended to penetrate the anterior prostatic capsule, but the procedures were not changed in two biopsy instruments. When abnormal findings were recognized on ultrasonography during biopsy, the biopsy needles were targeted to the abnormal lesion in some cases. However, the number of cores was not increased in these cases. Abnormal MRI findings did not affect the biopsy method in the present study. MRI-ultrasound fusion-guided biopsies were not carried out in this period. Biopsy was carried out by several operators, including urological residents.
Each core was gently removed from the biopsy needle, placed on filter paper and flattened. The paper was rolled and placed in a bottle containing 10% formalin. All biopsy cores were separately labeled, and two cores were embedded in one cassette.
In the last 56 of normal-notch cases and the first 48 longnotch cases, the biopsy tissue on the slides was scanned into a computer and the lengths of core tissues were measured in millimeters by tracing the scanned image manually along the shapes of the cores (Fig. 2) . This tracing was carried out using ImageJ Software (National Institutes of Health, Bethesda, MD, USA). 12 If tissue was fragmented, the total length was obtained by adding the lengths of all fragments.
All cancers were graded according to the Gleason scoring system, and insignificant cancer was defined using the Epstein criteria: clinical stage T1c, PSA density <0.15 ng/ mL, no Gleason pattern 4 or 5, fewer than three positive cores and <50% cancer per core. 13 
Assessment of pain and complications
After the biopsy, perceived pains at DRE, echo insertion, the first half of the biopsy (right lobe) and the second half of the biopsy (left lobe) were recorded using a six-level version of the FPS, with scores ranging from 0 for no pain to five for unbearable pain.
Complications after biopsy were surveyed by recording the occurrence of hematuria, urinary retention, fever >38.5°C and rectal bleeding requiring intervention.
Statistical analysis
Differences between medians and differences between means were evaluated using Mann-Whitney U-tests and Student's t-tests where appropriate. The v 2 -test was used for analyzing proportions. Multivariate analysis using a logistic regression model was carried out to evaluate the impact of age, PSA, prostate volume and biopsy instrument on prostate cancer detection.
All statistical analyses were carried out with SPSS (IBM, Armonk, NY, USA) for Windows. All reported P-values are from two-sided tests, and a P-value of ≤0.05 was considered to show a statistically significant difference.
Results

Patient characteristics
Median age, PSA and prostate volume were 69, 6.95 ng/mL and 32.0 mL in patients biopsied using the normal-notch needle, and were 71, 6.93 ng/mL and 38.5 mL in patients biopsied using the long-notch needle (Table 1) . PSA did not differ significantly between the two groups, but age and prostate volume were significantly higher in the long-notch group.
Sampled core length and cancer detection rate
The mean length of tissue taken by the long-notch needle was 22.4 mm (89.6% of the notch length), and it was significantly (P < 0.001) greater than the mean length of tissue taken by the normal-notch needle: 16.3 mm (85.8% of the notch length). In all parts of the biopsies, the tissue taken by the long-notch needle was significantly longer than that taken by the normal-notch needle ( Table 2 ).
The overall cancer detection rate was 42.0% (197/469) for the normal-notch needle and 51.1% (250/489) for the longnotch needle (P = 0.005). In patients with a prostate volume of 20-40 mL, the cancer detection rate for the long-notch needle was especially higher than that for the normal-notch needle (74.2% vs 47.5%, P < 0.001). In patients with a PSA of 4-10 ng/mL, the cancer detection rate for the long-notch needle was also significantly higher than that for the normalnotch needle (46.3% vs 37.2%, P = 0.018; Table 3 ). Multivariate analysis showed that the long-notch needle significantly improved the cancer detection (odds ratio 1.702, P < 0.001; Table 4 ). Table 5 shows pathological diagnosis of the biopsy. The distribution of the Gleason score differed significantly between the two groups, but the rates of the detection of insignificant cancer according to the Epstein criteria in the two groups were not significantly different. 
Pain and complications
The FPS scores could be collected from 62 patients who underwent TRNB using the normal-notch needle and 81 patients who underwent TRNB using the long-notch needle.
In the long-notch group, the average scores were 1.20 for the DRE, 1.85 for the probe insertion, 2.15 for the first half of the biopsy and 2.14 for the second half of the biopsy. None differed significantly from the corresponding score in the normal-notch group (Table 6 ). There were also no significant differences between longnotch and normal-notch groups with regard to the occurrence after biopsy of hematuria, urinary retention, fever >38.5°C or rectal bleeding requiring intervention (Table 6 ).
Discussion
In the present study, we showed that the novel biopsy instrument with a 25-mm side-notch could take longer tissue cores and had a significantly higher detection rate than that of the normal biopsy instrument, especially in patients with a prostate volume of 20-40 mL. The better detection of cancer in patients biopsied by the novel instrument was also shown in a multivariate analysis. This is the first report to evaluate prostate cancer detection using the novel biopsy instrument in prostate needle biopsy.
Since the first description of a sextant ultrasound-guided TRNB by Hodge et al., the technique has been modified many times.
14 A major concern in TRNB is that the anterior portion of the prostate gland, including the anterior peripheral and transition zones, is difficult to target by standard TRNB, particularly for larger glands. To take longer tissue samples and to reach the anterior portion of the prostate, we developed a biopsy instrument by extending the side-notch length and the stroke length before this study. Figure 3 shows TRUS images of the middle lobe of the prostate during biopsies using the normalnotch needle and the long-notch needle in the same patient. The long-notch needle could reach the far anterior portion of the prostate, and that is one reason it increased the cancer detection rate, especially in patients with a prostate volume of 20-40 mL. Approximately 10 years ago, several studies evaluated the clinical outcomes of biopsies made using an end-cutting biopsy instrument, the BioPince (Amedic), with stroke lengths of 23 and 33 mm. One found that the mean length of the sample tissues taken with a 33-mm stroke length was 23.11 mm, which was just 70% of the stroke length. 1 The other two also found the mean length of sample tissues taken with the 33-mm stroke to be less than the stroke length: 19.4 mm 10, 11 and 19.9 mm. 10, 11 However, there was no significant difference of the cancer detection rate when compared with that of the standard needle, and they concluded that the high failure rate of the BioPince needle limits its routine use. In the present study, sampling failures other than those due to technical error were not observed, and the mean length of sample tissues taken by the novel instrument was 22.4 mm. Therefore, this 25-mm side-notch needle is currently the most efficient instrument on the market that can take longer tissue and be used routinely in a clinical setting.
In the present study, a higher detection rate for the long-notch needle was also observed in patients with a prostate >40 mL, but that rate was not significantly different when compared with the corresponding rate for the normal-notch needle. An instrument with a much longer notch needle is expected to increase the detection rate in patients with prostate volumes >40 mL.
The present study did not examine how long a notch length is sufficient for prostate cancer detection. We previously reported 3-D prostate cancer model analysis results showing that nearly all prostate cancers with a total volume >0.5 mL can be detected in TRNB by using 14-18 cores taken with a cutting length of 22 mm. 9 Therefore, this 25-mm side-notch needle, for which the mean length of sampled cores was 22.4 mm, might be sufficient for diagnosing prostate cancers with a total volume >0.5 mL.
There is a growing concern about overdiagnosis of prostate cancer, especially in patients who might qualify for the diagnosis of insignificant cancer. In the present study, the rate of insignificant cancer detection was not increased by using the long-notch needle, and further study will be necessary to evaluate the impact of this needle on the detection and diagnosis of insignificant cancer.
One might expect more pain and complications to be associated with the use of the long-notch needle because of its longer stroke length, but FPS scores did not differ between the long-notch and normal-notch needles. The present study showed low rates of severe complications, such as high fever (0.2%), acute urinary retention (0.4%) and rectal bleeding requiring intervention (0.4%). These results were the same as the results of other studies using normal-notch needles. 15, 16 These results suggest that this novel biopsy instrument can be used safely in a clinical setting.
There were some limitations to the present study. A strict indication for biopsy was not defined in this study. The characteristics of patients in the long-notch group and the normal-notch group were not the same. It cannot be denied that indication for biopsy might gradually change with time. The higher mean age of the long-notch group might have increased the detection rate, whereas the larger prostate volume of the long-notch group might have decreased the detection rate. However, multivariate analysis to eliminate possible confounders affecting the detection rate also showed the long-notch needle improved the cancer detection significantly.
We did not usually use MRI to decide indication of biopsy in both groups, and MRI-ultrasound fusion-guided biopsies were not carried out during this period. Patients with negative MRI findings were not excluded from the indication for biopsy, even when MRI was carried out before biopsy. However, although not many in both groups, there would be some patients who avoided biopsy because their MRI did not show any abnormal findings. The number of them might be increasing, but it was practically difficult to grasp the precise number of them. Therefore, we could not evaluate how MRI affected the detection rate in the present study. This was another limitation of this study. However, before this study, we carried out a biopsy simulation study using 3-D prostate cancer models reconstructed from actual specimens, and reported longer cutting length improved the detection rate of prostate cancer due to an increase in the detection rate of anterior tumors. 9 In the present study, we showed that the long-notch needle not only had a significantly higher rate of prostate cancer detection, but also could take significantly longer tissue samples. These results agree with the prior study, and the prior study might strongly support that the long-notch needle has a significantly higher rate of prostate cancer detection due to an increase in the detection rate of anterior tumors in transrectal biopsy.
